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ABSTRACT 
 
The incidence of mesothelioma continues to rise and prognosis remains dismal due to 
resistance to conventional therapies and few novel treatment options. Failure to activate 
apoptotic cell death is a resistance mechanism that may be overcome by inhibition of anti-
apoptotic Bcl-2 proteins using BH3-mimetic drugs. We investigated the role of anti-apoptotic 
proteins in the radioresistance of mesothelioma, identifying clinically-relevant targets for 
radiosensitization and evaluating the activity of BH3-mimetics alone and in combination with 
radiotherapy in pre-clinical models. 
Mesothelioma cell lines 211H, H2052 and H226 exposed to BH3-mimetics demonstrated Bcl-
xL dependence that correlated with protein expression and was confirmed by genetic 
knockdown. The Bcl-xL inhibitor A1331852 exhibited cytotoxic (EC50 0.13-1.42 µmol/L) and 
radiosensitizing activities (sensitizer enhancement ratios 1.3-1.8). Cytotoxicity was associated 
with induction of mitochondrial outer membrane permeabilization and caspase-3/7 activation. 
Efficacy was maintained in a three-dimensional model in which combination therapy 
completely eradicated mesothelioma spheroids. Clinical applicability was confirmed by 
immunohistochemical analysis of Bcl-2 proteins in patient samples and radiosensitizing 
activity of A1331852 in primary patient-derived mesothelioma cells. 
Mesothelioma cells exhibit addiction to the anti-apoptotic protein Bcl-xL and their intrinsic 
radioresistance can be overcome by small molecule inhibition of this novel therapeutic target. 
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INTRODUCTION 
 
Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-associated cancer with 
dismal outcome (median survival <10 months) (1). Curative treatment is currently prevented 
by intrinsic resistance to chemo- and radiotherapy, whereby the underlying mechanisms are 
poorly understood. 
Ionizing radiation (IR) induces DNA damage that activates multiple stress pathways, including 
those mediated through p53. Unlike many cancers, p53 mutations are infrequent in MPM (2) 
perhaps because of the selective pressure imposed by asbestos-induced inflammation (1). 
This distinct disease aetiology likely necessitates development of mechanisms to resist death 
signals generated downstream of p53 activation.   
Intrinsic apoptosis is initiated by inactivation of anti-apoptotic Bcl-2 proteins, which leads to 
mitochondrial outer membrane permeabilization (MOMP) and consequential cell death either 
through canonical caspase-dependent apoptosis or via caspase-independent mechanisms 
(3).  
Bcl-2 proteins regulate apoptosis through interactions between pro- and anti-apoptotic 
partners (4), and the documented suppression of apoptosis in MPM cells by these proteins (5) 
identifies them as promising therapeutic targets in this disease (1,6). Small molecule mimetics 
of the pro-apoptotic BH3 domain antagonize anti-apoptotic Bcl-2 protein function, promoting 
cell death (7). Indeed the prototype pre-clinical BH3-mimetic ABT-737, which inhibits Bcl-2, 
Bcl-xL and Bcl-w, is active against MPM cells (8,9), and alternative strategies abrogating Bcl-
2 protein function also induced apoptosis in MPM (9-12). Exploitation of the apoptotic priming 
exhibited by MPM cells, and their reliance on suppression of cell death pathways downstream 
of p53, creates a therapeutic opportunity for BH3-mimetics both as single agents and in 
combination with cytotoxic agents including IR (1,6,8). The recent development of novel 
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inhibitors with improved selectivity and enhanced pharmacokinetic properties creates an 
opportunity for targeting individual Bcl-2 proteins in the clinic (13). 
Herein, we describe a specific role for Bcl-xL in the failure of MPM cells to execute apoptosis 
in response to IR, and demonstrate potent cytotoxic and radiosensitizing activities of the next-
generation Bcl-xL inhibitor A1331852 in multiple MPM models.   
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MATERIALS & METHODS 
 
Reagents 
All reagents were purchased from Sigma-Aldrich, unless otherwise stated. Inhibitors of Bcl-2 
proteins (A1155463, A1331852, ABT-199, ABT-263, UMI-77) were obtained from 
SelleckChem. 
 
Cell culture 
Mesothelioma cell lines MSTO-211H (211H) and NCI-H2052 (H2052) were provided by Sam 
Janes (University College London); NCI-H226 (H226) were supplied by John Lunec 
(University of Newcastle). Cells were maintained at 37 °C with 5% CO2 in Advanced DMEM/F-
12 medium supplemented with 10% FBS, L-glutamine (1 mmol/L), penicillin (50 units/mL) and 
streptomycin (50 µg/mL), and tested regularly for mycoplasma (Lonza). All experiments were 
performed within 10 passages of revival.  
 
Transcriptomic analysis 
RNAseq data were obtained from The Cancer Genome Atlas mesothelioma project (TCGA-
MESO). The absence of normal tissue samples prohibited fold-change analysis, so relative 
gene expression was assessed using an approach similar to calculation of expression rank 
product (14). For each patient (n=86), normalized mapped reads (FPKM) were ranked for 
expression and assigned a rank product.  
 
Immunohistochemistry 
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Formalin-fixed paraffin-embedded spheroid sections and clinical mesothelioma samples were 
subjected to antigen retrieval (Dako), blocked, and stained using antibodies to Ki67 (Dako 
#M724001-2, 1/100), active caspase-3 (Cell Signalling #9661, 1/500), Mcl-1 (Abcam #32087, 
1/500), Bcl-2 (Leica # NCL-L-bcl-2, 1/200) and Bcl-xL (Abcam #ab32370, 1/300) overnight at 
4 °C and HRP-conjugated secondary antibodies (Dako) at room temperature for 40 minutes. 
Staining was visualized using 3,3’-diaminobenzidine tetrahydrochloride (DAB, Dako); nuclei 
were counterstained with haematoxylin. Slides were digitally scanned and analysed using 
HALO software (PerkinElmer) to calculate an H-score for each sample based on the 
percentage of cells exhibiting mild, moderate or high staining intensity (ranging from 0 to 300). 
 
Cell viability 
Cell viability was assessed by CellTiterGlo (Promega) assay after 4 days of treatment. Cells 
were seeded overnight in 96-well plates and treated with inhibitors or vehicle control 4 hours 
prior to irradiation at room temperature (2 Gy). Irradiation was performed in a regularly 
calibrated X-ray cabinet (2.47 Gy/min, 195 kV, 15 mA, 0.5 mm Cu filter, X-Strahl). For caspase 
inhibition experiments, cells were pre-treated with QVD-OPh (QVD, Abcam) to a final 
concentration of 20 µmol/L for 1 hour, before exposure to A1331852 and IR (2 Gy). Cell 
viability was determined after 24 hours. Data were normalized to untreated controls or IR-only 
samples, and compared to controls by one-way ANOVA with post hoc Tukey test. Dose 
response parameters were obtained by fitting a 4-parameter dose response curve and were 
compared by F-test. 
 
Western immunoblotting 
Cells were treated with 5 Gy or sham irradiated, followed by a 24 hour incubation. Whole cell 
lysates were harvested before separation by SDS-PAGE, blotting, blocking, and probing with 
primary antibodies to β-tubulin (Abcam #ab21057, 1/1000), Bcl-xL (Abcam #ab32370, 
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1/1000), Mcl-1 (Abcam #ab32087, 1/1000), and Bcl-2 (Dako #M0887, 1/1000) overnight at 4 
°C, and HRP-conjugated secondary antibodies (Cell Signalling Technology, 1/5000) for 1 hour 
at room temperature. Antibody binding was visualized using ECL reagent (Thermo Fisher 
Scientific) and imaged by LI-COR Odyssey Fc. 
 
Knockdown of Bcl-xL expression 
Cells were transfected using Lipofectamine RNAi Max (Thermo Fisher Scientific) with two 
independent siRNAs (Dharmacon); target sequences GGACAGCAUAUCAGAGCUU and 
CCUACAAGCUUUCCCAGAA. Mock transfection and non-targeting siRNA acted as controls. 
Lysates were harvested and assays performed 48 hours post-transfection. 
 
Clonogenic survival assay 
Cells were seeded at densities that generated >50 colonies per well and drug treated 4 hours 
pre-irradiation. After >7 days, colonies were washed, fixed in methanol, and stained with 
crystal violet. Surviving fraction (SF) was calculated using plating efficiencies (PE) of 
mock/vehicle-treated or drug only-treated cells. Data were fitted using the linear quadratic 
equation and curves compared using an exact sum-of-squares F-test. Sensitizer 
enhancement ratios were calculated using mean inactivation doses determined from the linear 
quadratic model. Differences between treatment groups were analysed by two-way ANOVA.  
 
Immunofluorescence 
Cells were seeded on glass coverslips overnight (104 cells/cm2) before drug treatment and 
subsequent irradiation. Four hours later, cells were fixed, permeabilized, and blocked. 
Samples were immunostained using antibodies to Cytochrome C (BD Biosciences #556432, 
1/500) and Bax (Cell Signalling Technology #2772, 1/500) for 1 hour at 37 °C and fluorophore-
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conjugated secondary antibodies (Thermo Fisher Scientific, 1/500) for 1 hour at 37 °C. Nuclei 
were counterstained with DAPI (Dako). Five random fields-of-view were acquired using 
20x/0.8 objective on a Zeiss LSM780 confocal microscope. The number of cells exhibiting 
punctate Bax and Cytochrome C release was manually counted and computed as the 
proportion of total cells for >50 cells/experiment, and normalized to vehicle control. Data were 
compared by one-way ANOVA with post hoc Tukey test. Example images were obtained using 
a 63x/1.4 objective. 
 
Caspase-3/7 activity assay 
Caspase-3/7 activity was quantified using a Caspase-Glo 3/7 assay (Promega). Cells were 
seeded overnight before 4 hour drug treatment and subsequent irradiation. Data were 
normalized to peak activity and compared by one-way ANOVA with post hoc Tukey test.  
 
Spheroid growth 
H2052 cells were seeded in ultra-low attachment plates (100 cells/well, Corning). After 4 days, 
spheroids were treated with inhibitor (3 µmol/L) or vehicle for 6 hours before exposure to 5 
Gy. Brightfield imaging of spheroids was performed with a 5x/0.15 objective on a Zeiss Axio 
Vert.A1 microscope fitted with an AxioCam ICm1 camera, and volume estimated using 
Reconstruction and Visualization from a Single Projection (ReVISP) (15). Groups were 
compared at day 17 by one-way ANOVA with post hoc Tukey test. 
 
Isolation of primary mesothelioma cells 
Primary MPM cells were generated from surplus pleural fluid obtained during a therapeutic 
pleural aspiration under informed consent, cultured in conditions previously described for 
primary MPM cell lines (16) and used within two passages. Ethical approval for derivation and 
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use of primary MPM cells was provided by NHS Research Scotland Greater Glasgow & Clyde 
Biorepository (ref. 2014/175). 
 
Statistical analysis 
Statistical analyses were performed using R 3.5.0 (17) with the addition of the ‘drc’ package 
(18), as described for each experimental technique. Figures represent means±SD of 3 
independent experiments, unless otherwise indicated. 
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RESULTS 
 
Mesothelioma cells depend on Bcl-xL function for survival 
Expression of Bcl-2 proteins in MPM was investigated using transcriptomic data within TCGA. 
Genes encoding Mcl-1 (MCL1), Bcl-2 (BCL2) and Bcl-xL (BCL2L1) were highly expressed in 
MPM, particularly MCL1 and BCL2L1 (Fig. 1A). Expression was consistent across all 
histological subtypes: epithelioid (57/86), biphasic (22/86), sarcomatoid (2/86) and diffuse 
malignant (5/86). High expression of both pro- and anti-apoptotic genes (Supplementary Fig. 
S1) supports the theory that MPM is primed for apoptotic death (8,19,20) and strengthens the 
rationale for targeting Bcl-2 proteins. High expression of genes encoding diagnostic markers 
of MPM (mesothelin, calbindin 2, keratin 5 and podoplanin) and low expression of exclusion 
markers (carcinoembryonic antigen related cell adhesion molecule 3; estrogen receptor 1) 
validated the samples studied and the expression ranking approach (21-23). 
At the protein level, MPM samples exhibited low expression of active caspase-3 (Fig. 1B-C), 
indicating inhibition of apoptosis, and robust staining for at least one major anti-apoptotic Bcl-
2 protein. Consistent with transcriptomic data, Mcl-1 and Bcl-xL levels were generally higher 
than Bcl-2, although some samples (e.g. patient 17) preferentially expressed Bcl-2.  
Functional roles of Bcl-2 proteins were investigated using a panel of cell lines representing 
epithelioid (H226), sarcomatoid (H2052) and biphasic (211H) MPM subtypes. Expression of 
Mcl-1, Bcl-2 and Bcl-xL varied, with 211H cells exhibiting robust expression of all three 
proteins, H2052 expressing primarily Bcl-xL, and H226 exhibiting intermediate Mcl-1 and low 
Bcl-2 and Bcl-xL expression (Fig. 2A). Protein expression was unaltered by exposure to IR (5 
Gy). Hence, different MPM tumours exhibit different patterns of Bcl-2 protein expression, 
which might confer differential dependencies on particular anti-apoptotic protein function. 
These dependencies were investigated using chemical BH3-profiling (24,25). Viability assays 
of MPM cells treated with BH3-mimetic inhibitors specific to Mcl-1 (UMI-77), Bcl-2 (ABT-199) 
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and Bcl-xL (A1155463) showed that Mcl-1 inhibition had minimal effect, while Bcl-2 inhibition 
had modest activity in 211H cells and minimal activity in the other cell lines (Fig. 2B). In 
contrast, Bcl-xL inhibition markedly reduced viability of 211H and H2052 cells (relative 
viabilities 0.28 and 0.27 at 1 µmol/L, respectively) and had modest activity against H226 cells 
(relative viability 0.18 at 10 µmol/L). Comparison with immunoblot data revealed a broad 
association between sensitivity to BH3-mimetics and Bcl-2 protein expression.  
Survival dependency on Bcl-xL was corroborated by knockdown of expression using two 
independent siRNA constructs. Downregulation, confirmed by immunoblot (Fig. 2C), was 
associated with significant reductions in cell viability in all three cell lines (Fig. 2D). 
 
Bcl-xL inhibition reduces mesothelioma cell survival through activation of MOMP 
Having identified Bcl-xL as the most promising target, a second-generation inhibitor with 
improved potency and oral bioavailability (13), A1331852, was selected for further studies. 
A1331852 exhibited submicromolar potency against cells with high Bcl-xL expression, (EC50 
values 0.270 µmol/L (95% confidence interval (CI) 0.139-0.400) and 0.133 µmol/L (95% CI 
0.110-0.156) in 211H and H2052 cells respectively, Fig. 3A). Modest potency in H226 cells 
(EC50 1.415 µmol/L, 95% CI 0.590-2.240) was consistent with lower Bcl-xL expression. 
Ionizing radiation (IR, X-rays) induces apoptosis via the intrinsic pathway, and radioresistance 
of cancer cells is frequently associated with loss of this response. We hypothesized that 
combining Bcl-xL inhibition with IR would enhance efficacy and assessed this by measuring 
cell viability. Radiation alone (2 Gy) induced only a modest reduction in viability 
(Supplementary Fig. S2) but a therapeutic interaction with A1331852 was indicated by a 
significant reduction in drug EC50 in 211H (EC50 0.032 µmol/L, 95% CI 0.016-0.048) and 
H2052 (0.031 µmol/L, 95% CI 0.025-0.036) cells (Fig. 3A). In H226 cells, an effect was 
detectable but failed to reach statistical significance (EC50 0.502 µmol/L, 95% CI 0.191-0.813). 
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To investigate the specificity of these effects and understand the mechanisms involved, effects 
of A1331852 on apoptosis were determined at early time-points. We measured cellular MOMP 
8 hours after treatment with A1331852 +/- IR (Fig. 3B, Supplementary Fig. S3). While IR alone 
(2 Gy) failed to induce MOMP (Fig. 3C), treatment with approximately isotoxic concentrations 
of A1331852 (viability ~40%; 1 µmol/L, 0.3 µmol/L and 3 µmol/L for 211H, H2052 and H226 
respectively) robustly induced MOMP in 211H and H2052 cells. Maximal induction of MOMP 
was achieved in all cell lines by combining A1331852 with IR (2 Gy): 15.1, 11.9, and 4.9 fold 
increases in MOMP were observed in 211H, H2052, and H226 cells respectively. 
Consistent with these observations, IR alone failed to increase caspase-3/7 activity, whereas 
A1331852 caused a marked increase in all three cell lines (Fig. 3D) and combination treatment 
further enhanced caspase-3/7 activation in cells expressing higher levels of Bcl-xL (211H and 
H2052), but not H226 cells. 
The caspase-dependency (26,27) of A1331852-mediated death was next investigated using 
a broad-spectrum caspase inhibitor (QVD) in a 24 hour experiment, during which time 
canonical apoptosis is active. A1331852 reduced viability of MPM cells within 24 hours (Fig. 
3E), whereas IR alone had no impact; and no combination-effects were apparent in this short-
term assay. In H2052 and H226 cells, pre-treatment with the caspase inhibitor QVD partially 
protected cells against A1331852-mediated loss of viability, both with and without IR, 
indicating caspase-dependent apoptosis as the primary mechanism of cell death. In 211H 
cells, however, A1331852 reduced viability much less effectively over 24 hours than in longer 
term assays (e.g. Fig. 3A), implicating an alternative pathway of death in this cell line. 
Supporting this, and despite apparent activation of caspase-3/7 (Fig. 3D), QVD failed to 
protect 211H cells against A1331852-induced cell death (Fig. 3E), suggesting a MOMP-
activated but caspase-independent mechanism of death, as previously described (27). 
These findings indicate that the single agent and radiosensitizing activities of A1331852 are 
mediated through induction of MOMP, and that cell death proceeds via caspase-dependent 
apoptosis or in a caspase-independent manner depending on the cell line. Rapid activation of 
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MOMP after exposure to A1331852 supports our hypothesis that MPM cells are primed for 
mitochondrial cell death, which is otherwise suppressed by Bcl-xL. 
 
Bcl-xL inhibition sensitizes mesothelioma cells to ionizing radiation 
The radiosensitizing effects of A1331852 were validated by clonogenic survival, the gold 
standard measure of sensitivity to IR. IR alone caused modest reductions in clonogenicity, 
(SF4Gy values 0.105, 0.156 and 0.184 for 211H, H2052 and H226 cells, respectively, Fig. 4A). 
To assess radiosensitization, cells were pre-incubated with A1331852 at concentrations that 
activated MOMP (Fig. 3C). Single agent activity of A1331852 was confirmed by reduced 
plating efficiency in H2052 and H226 cells (Supplementary Fig. S4A) and A1331852 
significantly increased radiosensitivity, reducing SF4Gy values to 0.032, 0.035, 0.095 for 211H, 
H2052, and H226, respectively (Fig. 4A). Formal quantification revealed clinically meaningful 
sensitizer enhancement ratios (SER) of 1.55, 1.80 and 1.30 in 211H, H2052 and H226 cells 
respectively.  
To confirm the specificity of this effect and identify other candidates for clinical development, 
alternative Bcl-xL inhibitors were evaluated. Despite exhibiting lower single agent activity, the 
Bcl-xL-specific tool compound A1155463 and the Bcl-xL, Bcl-2 and Bcl-w inhibitor ABT-263 
radiosensitized MPM cells with high Bcl-xL expression, but failed to overcome radioresistance 
in H226 cells (Supplementary Fig. S4A-D). Finally, siRNA knockdown of Bcl-xL reduced 
colony formation (Supplementary Fig. S4E) and effectively sensitized all three MPM cell lines 
to IR (Fig. 4B).  
These findings indicate that chemical inhibition of Bcl-xL has potential as single agent and 
radiosensitizing therapy for MPM, and identify the clinically translatable compound A1331852 
as the most promising agent in this class. 
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Bcl-xL inhibition shows efficacy against mesothelioma spheroids and patient-derived cells 
Despite multiple attempts, we were unable to generate xenograft models of MPM that could 
support experiments evaluating radiotherapy-drug combinations. We therefore validated the 
therapeutic potential of A1331852 in MPM spheroids generated from H2052 cells, which 
resemble those observed in the pleural effusions of patients (28,29). This model expressed 
Bcl-xL and recapitulated clinical features including peripheral Ki67-positive proliferative cells 
and low baseline caspase-3 activation (Supplementary Fig. S5).  
Spheroids treated with vehicle alone grew to an average volume of 0.341 mm3 over 17 days 
(Fig. 5A). Single agent treatment with either IR (5 Gy) or A1331852 (3 µmol/L) caused 
measurable but temporary growth delay (volumes 0.158 and 0.074 mm3 respectively, on day 
17). In contrast, combination treatment caused complete and permanent regression such that 
spheroids were undetectable by day 12. 
For further validation, tumour cells were isolated from the pleural effusion of a patient with 
epithelioid MPM (16) and treated with the radiotherapy-drug combination. In a single 
experiment, irradiation (2 Gy, Supplementary Fig. S6) and single agent treatment with 
A1331852 had modest effects on viability (EC50 2.894 µmol/L, 95% CI 1.106-4.681) (Fig. 5B) 
but a striking therapeutic interaction between drug and IR was observed (EC50 0.153 µmol/L, 
95% CI 0.052 to 0.254), supporting the clinical applicability of this novel combination. 
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DISCUSSION 
 
This pre-clinical study demonstrates the therapeutic potential of novel BH3-mimetics in MPM, 
both as single agents and radiosensitizers. Targeting Bcl-xL has been shown to sensitize MPM 
cells to different classes of chemotherapy (8,10,12,30), and the radiosensitizing potential of 
broad-spectrum BH3-mimetics such as ABT-737 has been demonstrated in other 
malignancies (31-33). We show for the first time that the Bcl-xL inhibitor A1331852 promotes 
MOMP in response to IR, leading to potent radiosensitization of primary and established MPM 
cells representing all histological disease subtypes. Combination efficacy was confirmed in a 
multicellular 3D model of MPM, a disease in which the presence of cell aggregates in pleural 
fluid correlates with disease malignancy (28). Since expression of Bcl-2 proteins is influenced 
by culture dimensionality (34), efficacy in 3D culture is a critical step in preclinical validation. 
Clinical studies of BH3-mimetics have indicated ‘on-target’ haematological toxicity to be dose-
limiting (35,36). The radiosensitizing activity of Bcl-xL inhibition raises the possibility of 
shortened treatments at lower drug concentrations, which may mitigate bone marrow 
suppression. In contrast to systemic chemotherapy (13), targeted thoracic radiotherapy is 
unlikely to exacerbate the haematological toxicity of Bcl-xL inhibition.  
Genomic analysis of MPM samples has revealed a paucity of oncogenic mutations suitable 
for therapeutic targeting (2), supporting the adoption of broader, combinatorial strategies (1), 
such as reported here. These considerations, and the scarcity of representative experimental 
models of MPM, have contributed to neglect of this industrial disease of unmet need. By 
demonstrating dependency on Bcl-xL, our work identifies an important mechanism of therapy 
resistance and identifies a promising therapeutic strategy involving modulation of the apoptotic 
threshold in MPM cells. 
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FIGURE LEGENDS 
 
Figure 1. Bcl-2 proteins are highly expressed in clinical mesothelioma samples. 
(A) Expression of MCL1, BCL2 and BCL2L1 genes determined across MPM subtypes from 
patient transcriptomic data (TCGA). Data were plotted for each patient (n=86), with median 
expression represented by lines. Rank product quartiles are indicated. (B) Clinical 
mesothelioma tumour sections stained for Ki67 and apoptotic proteins. Samples were 
counterstained with haematoxylin. (C) Automatic stain quantification represented by H-score. 
Box and whiskers were plotted according to the Tukey method (n=18). 
 
 
Figure 2. Mesothelioma cells depend on Bcl-xL function for survival. 
(A) Immunoblotting showing expression of Mcl-1, Bcl-2 and Bcl-xL proteins in MPM cells. Cells 
were treated with 5 Gy X-rays or sham irradiation and lysates harvested after 24 hours. (B) 
Relative viability of MPM cells treated with BH3-mimetics targeting Mcl-1, Bcl-2 and Bcl-xL 
measured 96 hours after treatment. (C) siRNA-mediated reduction in Bcl-xL expression 
assessed by immunoblotting at 48 hours. (D) Relative viability of cells transfected with siRNA 
constructs for 48 hours determined after 96 hours. Bars represent mean±SD of 3 independent 
experiments. Groups were compared by one-way ANOVA with post hoc Tukey test. *** 
P<0.001 compared to vehicle or mock transfected controls. 
 
 
Figure 3. A1331852 activates apoptosis in response to IR in mesothelioma cells. 
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(A) Relative viability of MPM cells measured 96 hours after treatment with A1331852, alone 
or in combination with 2 Gy X-rays. Points represent mean±SD of 3 independent experiments; 
EC50 values were determined by fitting a 4-parameter dose response curve. (B) An example 
of the MOMP phenotype in H2052 cells assessed by immunofluorescent staining of Bax 
(green) and Cytochrome C (red), 8 hours after exposure to A1331852 and IR (2 Gy X-rays). 
Nuclei counterstained with DAPI (blue); scale bar 20 µm. (C) Quantification of fold induction 
of MOMP. (D) Activation of caspase-3/7 measured following 24 hour treatment with A1331852 
and IR (2 Gy X-rays), normalized for peak activity. (E) Relative viability of cells treated with 
A1331852 and IR (2 Gy X-rays) assessed after 24 hours, with or without pre-treatment with 
the caspase inhibitor QVD. Bars represent mean±SD of 3 independent experiments and were 
compared by one-way ANOVA with post hoc Tukey test. *** or ### P<0.001, ** or ## P<0.01, 
* or # P<0.05 (* compared to 0 Gy DMSO, # comparison as indicated). 
 
 
Figure 4. Bcl-xL inhibition sensitizes mesothelioma cells to ionizing radiation. 
(A) Clonogenic survival of cells treated with IR (X-rays) alone or in combination with 
A1331852. (B) Clonogenic survival of cells treated with IR (X-rays) alone or in combination 
with siRNAs targeting Bcl-xL. Points represent mean±SD of 3 independent experiments, and 
were fitted using the linear quadratic model; curves were compared by F-test. *** P<0.001, ** 
P<0.01 compared to vehicle control (DMSO) or mock treated samples. Sensitizer 
enhancement ratios (SER) were calculated according to the mean inactivation dose method. 
 
 
Figure 5. A1331852 exhibits efficacy in advanced pre-clinical models of mesothelioma. 
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(A) Growth of MPM spheroids treated with IR (5 Gy X-rays) and A1331852 (3 µmol/L) 
measured over 17 days. H2052 cells were grown as spheroids and treated at day 0. Points 
represent mean±SD of 3 independent experiments, compared by one-way ANOVA with post 
hoc Tukey test at day 17. ** P<0.01, * P<0.05, comparison as indicated. Scale bar 1 mm. (B) 
Relative viability of primary MPM cells measured 96 hours after treatment with A1331852, 
alone or in combination with 2 Gy X-rays. Points represent mean±SD of 2 technical replicates 
from a single experiment; EC50 values were determined by fitting a 4-parameter dose 
response curve.  
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